The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
Deucravacitinib in patients with moderate-to-severe scalp psoriasis: Results from the phase IIIb/IV PSORIATYK SCALP trial
|
The ongoing phase IIIb/IV multicenter, randomized, double-blind PSORIATYK SCALP trial (NCT05478499) is evaluating the safety and efficacy of deucravacitinib (n = 103), an oral, selective, allosteric TYK2 inhibitor, vs placebo (n = 47) in adult patients with moderate-to-severe scalp psoriasis.1 This trial includes patients with less extensive overall psoriasis (BSA involvement 3–10%) compared with the phase III POETYK PSO-1 and POETYK PSO-2 trials. Interim results were presented by Mark Lebwohl at the EADV 2024 Congress. 1 |
| Key learnings |
|
The primary endpoint was met; at Week 16, ss-PGA 0/1 response rates were 48.5% in the deucravacitinib group vs 13.7% in the placebo group (p < 0.0001). Among patients with sPGA ≥3, ss-PGA 0/1 response rates in the deucravacitinib (n = 96) vs placebo groups (n = 47) were 50.0% vs 12.8% (p < 0.0001). |
|
At Week 16, deucravacitinib when compared to placebo improved PSSI 90 response rates (38.8% vs 2.0%; p < 0.0001), CFB scalp-specific itch NRS (−3.2 vs −0.7; p < 0.0001), and sPGA 0/1 response rates in patients with sPGA ≥3 (51.0% vs 4.3%; p < 0.0001), BSA involvement 3–10% (42.9% vs 5.3%; p < 0.0001) and BSA involvement >10% (57.6% vs 0.0%; p = 0.0004). |
|
Safety findings were consistent with the known profile of deucravacitinib, with no new signals observed. |
|
Results from the PSORIATYK SCALP trial suggest that deucravacitinib is well tolerated and effective in patients with moderate-to-severe scalp psoriasis, including patients with less extensive overall body psoriasis. |
Abbreviations: BSA, body surface area; CFB, change from baseline; EADV, European Academy of Dermatology and Venereology; NRS, numeric rating scale; PSSI 90, ≥90% improvement from baseline in Psoriasis Scalp Severity Index; sPGA, static Physician Global Assessment; sPGA 0/1; sPGA score of 0 or 1; ss-PGA 0/1, scalp-specific Physician Global Assessment score of 0 or 1; TYK2, tyrosine kinase 2.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
